Milameline

Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.[1]

  • Changing the O-methyl aldoxime to an O-propargyl oxime instead gives a separate molecule called RU 35986.[2]
Milameline
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • (E)-N-methoxy-1-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)methanimine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ECHA InfoCard100.220.595
Chemical and physical data
FormulaC8H14N2O
Molar mass154.213 g·mol−1
3D model (JSmol)
SMILES
  • N(/OC)=C\C1=C\CCN(C)C1

See also

References
  1. Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11–12): 877–82. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.
  2. Broadley, Kenneth J.; Kelly, David R. (2001). "Muscarinic Receptor Agonists and Antagonists". Molecules. 6 (3): 142–193. doi:10.3390/60300142. ISSN 1420-3049. PMC 6236374.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.